Eikon Therapeutics

EIKN · NASDAQ

$8.18+$0.48 (+6.23%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $7.70

EIKN analyst rating

BuyConsensus of 7 analysts over the last 12 months. 86% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform1
Sell0

12-month price target · 7 analysts

Average $23.97 (+193.0% upside)

Low: $4.04
Now: $8.18
High: $33.60

Upgrades and downgrades

The latest rating actions, newest first

EIKN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 16, 2026	Initiates	Buy	$23.00	8%
Wedbush	Aug 14, 2026	Maintains	Underperform	$5.00 → $4.00	39%
Wedbush	May 12, 2026	Maintains	Underperform	$7.00 → $5.00	39%
Wedbush	Mar 31, 2026	Maintains	Underperform	$7.00	39%
Cantor Fitzgerald	Mar 2, 2026	Initiates	Overweight	—	0%
JP Morgan	Mar 2, 2026	Initiates	Overweight	$29.00	40%
B of A Securities	Mar 2, 2026	Initiates	Buy	$34.00	64%
Mizuho	Mar 2, 2026	Initiates	Outperform	$26.00	54%
Morgan Stanley	Mar 2, 2026	Initiates	Overweight	$32.00	47%
Wedbush	Feb 26, 2026	Initiates	Underperform	$7.00	39%

The case for and against

Updated Oct 15, 2026

Bull case

Eikon Therapeutics is positioned favorably because its diversified late-stage pipeline—EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006—creates multiple shots on goal in addressing serious unmet medical needs through its proprietary drug-discovery and clinical-development platform. The company’s positive outlook is reinforced by the possibility of stronger-than-expected clinical data from key assets, which could materially improve the profile of the franchise and validate its single-segment biopharmaceutical model. Additional upside could come from higher-than-expected income from in-licensed products or commercial partnerships, as well as a significant reduction in cash burn, all of which would strengthen financial resilience and support long-term value creation.

Bear case

Eikon Therapeutics is viewed negatively because Q2 brought an $88.4M net loss, or ($1.63)/share, and operating expenses ran above expectations, while cash, cash equivalents, and marketable securities fell to $531.2M from $596.0M in Q1. Its pipeline still lacks a clearly de-risked lead beyond EIK1001, and EIK1003 showed only modest activity with a 14.3% ORR as monotherapy and 24.5% ORR with paclitaxel in heavily pretreated patients, leaving efficacy and differentiation concerns unresolved. EIK1004 and EIK1005 remain early with mechanistic and competitive headwinds, EIK1006 is only guided to an IND submission by YE:26, and the company continues to burn cash despite expecting runway into 2H:27.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.